中文版 | English
题名

Chinese herbal medicine Shufeng Jiedu Capsule for patients with mild to moderate coronavirus disease 2019 (COVID-19): Protocol for a randomized, blinded, placebo control trial

作者
发表日期
2023-09-01
DOI
发表期刊
ISSN
1876-3820
EISSN
1876-3839
卷号62
摘要
Introduction: Most current Coronavirus disease (COVID-19) infected cases are now diagnosed as mild to moderate. Symptoms such as sore throat, headache, nasal congestion, cough, etc. lack effective treatment for their relief. The registered Chinese herbal medicine Shufeng Jiedu Capsule (SFJD) has been used to treat different epidemics like influenza A virus subtype H1N, and has been shown to improve symptoms such as fever, sore throat, headache, nasal congestion and cough. It has also been widely used to treat COVID-19 in China. This study aims to verify the efficacy and safety of SFJD in patients with mild and moderate COVID-19 infection. Methods: This study is designed as a randomized, blind, placebo control trial. A total of 220 patients in each group will receive either SFJD or placebo three times a day for five days, in addition to standard medical care. Participants will be assessed at baseline, during the treatment period, during the period of isolation in hospital and after hospital discharge on day 7 and 14. The primary outcome is time to alleviation of all COVID-19 related symptoms, including cough, stuffy nose, sore throat, fever or chills, muscle/joint pain, headache, fatigue, etc. Secondary outcomes are time to alleviation of individual COVID-19 related symptoms, time to SARS-CoV-2 virus reverse transcription polymerase chain reaction (RT-PCR) turning to negativity, changes in inflammatory parameters (leukocyte, lymphocyte, C-reactive protein (CRP), serum procalcitonin (PCT), inflammatory factor (Interleukin-6), CD4/CD8 cells), the amount of lung inflammation as ascertained by chest CT and adverse events. Discussion: The study is expected to provide evidence to explore indications and usage of SFJD for COVID-19. The design and methodology could be relevant to research on Chinese herbal medicine for other infectious diseases. Additionally, the results from the follow-up period will provide information on potential longer term symptom alleviation (14 days post COVID-19). Trial registration: ISRCTN14236594, Registered on 3 May 2022.
关键词
相关链接[Scopus记录]
收录类别
语种
英语
学校署名
其他
资助项目
National Science and Technology Infrastructure Program[2018YFE0102300];Xiamen Municipal Bureau of Science and Technology[3502Z2021YJ12];
WOS研究方向
Integrative & Complementary Medicine
WOS类目
Integrative & Complementary Medicine
WOS记录号
WOS:001069008800001
出版者
Scopus记录号
2-s2.0-85169310796
来源库
Scopus
引用统计
被引频次[WOS]:1
成果类型期刊论文
条目标识符http://sustech.caswiz.com/handle/2SGJ60CL/559649
专题南方科技大学第二附属医院
作者单位
1.Centre for Evidence-Based Chinese Medicine,Beijing University of Chinese Medicine,Beijing,100029,China
2.The Third People's Hospital of Shenzhen,the Second Affiliated Hospital to Southern University of Science and Technology,Shenzhen,518112,China
3.HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center,Hamburg-Eppendorf,Hamburg,20251,Germany
4.Institute of Health and Social Care,London South Bank University,London,United Kingdom
推荐引用方式
GB/T 7714
Lu,Chun li,Yang,Liu qing,Liu,Xue han,et al. Chinese herbal medicine Shufeng Jiedu Capsule for patients with mild to moderate coronavirus disease 2019 (COVID-19): Protocol for a randomized, blinded, placebo control trial[J]. European Journal of Integrative Medicine,2023,62.
APA
Lu,Chun li.,Yang,Liu qing.,Liu,Xue han.,Jin,Xin yan.,Wang,Fu xiang.,...&Liu,Jian ping.(2023).Chinese herbal medicine Shufeng Jiedu Capsule for patients with mild to moderate coronavirus disease 2019 (COVID-19): Protocol for a randomized, blinded, placebo control trial.European Journal of Integrative Medicine,62.
MLA
Lu,Chun li,et al."Chinese herbal medicine Shufeng Jiedu Capsule for patients with mild to moderate coronavirus disease 2019 (COVID-19): Protocol for a randomized, blinded, placebo control trial".European Journal of Integrative Medicine 62(2023).
条目包含的文件
条目无相关文件。
个性服务
原文链接
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
导出为Excel格式
导出为Csv格式
Altmetrics Score
谷歌学术
谷歌学术中相似的文章
[Lu,Chun li]的文章
[Yang,Liu qing]的文章
[Liu,Xue han]的文章
百度学术
百度学术中相似的文章
[Lu,Chun li]的文章
[Yang,Liu qing]的文章
[Liu,Xue han]的文章
必应学术
必应学术中相似的文章
[Lu,Chun li]的文章
[Yang,Liu qing]的文章
[Liu,Xue han]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
[发表评论/异议/意见]
暂无评论

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。